DrugPatentWatch Database Preview
Sun Pharm Inds Company Profile
What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?
SUN PHARM INDS has two hundred and twenty-nine approved drugs.
There are fourteen US patents protecting SUN PHARM INDS drugs. There are four tentative approvals on SUN PHARM INDS drugs.
Summary for Sun Pharm Inds
| US Patents: | 14 |
| Tradenames: | 168 |
| Ingredients: | 157 |
| NDAs: | 229 |
Drugs and US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-001 | May 25, 2012 | BX | RX | Yes | No | 9,089,534 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Sun Pharm Inds Ltd | GABAPENTIN | gabapentin | CAPSULE;ORAL | 077242-002 | Aug 24, 2006 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Sun Pharm Inds Ltd | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 091118-004 | Sep 25, 2014 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Ltd | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-001 | Jul 11, 2012 | 5,908,838 | ➤ Sign Up |
| Sun Pharm Inds Inc | ULTRAVATE | halobetasol propionate | CREAM;TOPICAL | 019967-001 | Dec 27, 1990 | 4,619,921 | ➤ Sign Up |
| Sun Pharm Inds Inc | LAC-HYDRIN | ammonium lactate | LOTION;TOPICAL | 019155-001 | Apr 24, 1985 | 4,105,783 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-01-07 |
| ➤ Subscribe | Capsules | 35 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Capsules | 30 mg and 40 mg | ➤ Subscribe | 2012-12-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2016-05-16 |
International Patents for Sun Pharm Inds Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2836228 | ➤ Sign Up |
| Brazil | 0113102 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 0224172 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Sun Pharm Inds Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014 00037 | Denmark | ➤ Sign Up | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
| 2012 00035 | Denmark | ➤ Sign Up | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105 |
| C0002 | Belgium | ➤ Sign Up | PRODUCT NAME: REPAGLINIDE; REGISTRATION NO/DATE: EU/1/98/076/001 19980817 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
